2018 Will Be Transformative For Migraine Treatment
Pharma & Healthcare / Canada / Fri 22 Sep, 2017
The approval of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies for migraine prevention will be one of the standout developments in the central nervous system drugs sector in 2018. Novartis and Amgen will be first to market with Aimovig, followed closely by Eli Lilly and Teva Pharmaceutical Industries, and pricing will be a